Immunovant Fiscal Q4 Loss Widens; Shares Up Pre-Bell
MT Newswires Live
May 20
Immunovant (IMVT) reported a fiscal Q4 net loss Wednesday of $0.73 per diluted share, widening from a $0.64 loss a year earlier.
Analysts polled by FactSet expected a $0.59 loss.
As expected, no revenue was reported for the quarter ended March 31.
The company's cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease, it said.
Immunovant shares were up 27% in premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.